<DOC>
	<DOCNO>NCT00432276</DOCNO>
	<brief_summary>The purpose study compare effect add alogliptin , daily ( QD ) , ongoing treatment regimen pioglitazone HCl metformin patient inadequate glycemic control .</brief_summary>
	<brief_title>Efficacy Alogliptin Pioglitazone Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Despite introduction new class medication glycemic control , half adult type 2 diabetes mellitus ( T2DM ) achieve glycosylated hemoglobin level less 7.0 % , American Diabetes Association recommend glycosylated hemoglobin goal . The rise incidence type 2 diabetes mellitus along limitation currently available treatment suggest need new therapy glycemic control along increase requirement combination therapy type 2 diabetes mellitus . Thiazolidinediones increase glucose utilization , decrease gluconeogenesis , increase glucose disposal incompletely understand mechanism one associate bind drug nuclear receptor know peroxisome proliferator-activated receptors-gamma . Peroxisome proliferator-activated receptors-gamma find tissue important insulin action , adipose tissue , skeletal muscle , liver . The great concentration peroxisome proliferator-activated receptors-gamma receptor adipose tissue . Thiazolidinediones reduce insulin resistance enhance insulin sensitivity muscle cell , adipose tissue , hepatic cell ( inhibit hepatic gluconeogenesis ) direct impact insulin secretion . Thus , thiazolidinediones improve glycemic control result reduce level circulate insulin . Pioglitazone HCl ( ACTOS® ) thiazolidinedione develop Takeda Chemical Industries , Ltd. ( Osaka , Japan ) . Pioglitazone depend presence insulin mechanism action . Worldwide clinical investigation show , adjunct diet exercise , pioglitazone improve glycemic control use monotherapy , combination commonly use antidiabetic medication ( ie , sulfonylurea , metformin , insulin ) . SYR-322 ( alogliptin ) selective , orally available inhibitor dipeptidyl peptidase IV currently development Takeda Global Research &amp; Development Center , Inc. treatment type 2 diabetes mellitus . Dipeptidyl peptidase IV primary enzyme involve vivo degradation least 2 peptide hormone release response nutrient ingestion , namely glucagon-like peptide-1 glucose-dependent insulinotropic peptide . Both peptide exert important effect islet β-cells stimulate glucose-dependent insulin secretion regulate β-cell proliferation cytoprotection . Glucagon-like peptide-1 also inhibit gastric emptying , glucagon secretion , food intake . The glucose-lowering action glucagon-like peptide-1 , glucose-dependent insulinotropic peptide , preserve patient type 2 diabetes . Given complementary mechanism action alogliptin ( stimulation insulin secretion ) pioglitazone ( enhancement insulin sensitivity ) absence overlap safety risk , introduction combination therapy patient T2DM could potentially show enhanced glycemic control allow patient reach maintain HbA1c goal effectively . This study design determine addition alogliptin combination pioglitazone metformin effective achieve glycemic control without increase safety risk versus titration pioglitazone 45 mg metformin patient type 2 diabetes mellitus experience inadequate glycemic control current regimen metformin .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Has historical diagnosis type 2 diabetes mellitus . Meets one following : Has inadequately control ( HbA1c 7 % 10 % , inclusive ) stable dose great equal 1500 mg ( maximum tolerate dose ) metformin 30 mg pioglitazone Has inadequately control ( define HbA1c ≥7.5 % ) combination therapy include metformin another oral antidiabetic agent ( ie , sulfonylureas , rosiglitazone maleate , pioglitazone 15 mg , etc ) . Subjects combination therapy include DPP4 inhibitor exclude . No treatment antidiabetic agent metformin pioglitazone . Body mass index great equal 23 kg/m^2 less equal 45 kg/m^2 . Fasting plasma Cpeptide concentration great equal 0.8 ng/mL . Systolic blood pressure le 160 mmHg diastolic pressure le 100 mmHg . Hemoglobin great equal 12 g/dL male great equal 10 g/dL female . Alanine aminotransferase less equal 2.5 x upper limit normal . Serum creatinine le 1.5 mg/dL male less 1.4 mg/dL female . Thyroidstimulating hormone level less equal upper limit normal range patient clinically euthyroid . Females childbearing potential sexually active must agree use adequate contraception , neither pregnant lactating Screening throughout duration study . Able willing monitor blood glucose concentration home glucose monitor . No major illness debility investigator 's opinion prohibit patient complete study . Urine albumin/creatinine ratio great 1000 μg/mg . History cancer , squamous cell basal cell carcinoma skin , full remission least 5 year prior Screening . History bladder cancer . History laser treatment proliferative diabetic retinopathy within 6 month prior Screening . Patients unexplained microscopic hematuria great +1 , confirm repeat testing . History treat diabetic gastroparesis . History gastric bypass surgery . New York Heart Association Class IIV heart failure regardless therapy . History coronary angioplasty , coronary stent placement , coronary bypass surgery , myocardial infarction within 6 month prior Screening . History hemoglobinopathy may affect determination glycosylated hemoglobin . History infection hepatitis B , hepatitis C , human immunodeficiency virus . History psychiatric disorder affect patient 's ability participate study . History angioedema association use angiotensinconverting enzyme inhibitor angiotensinII receptor inhibitor . History alcohol abuse substance abuse within 2 year prior Screening . Receipt investigational drug within 30 day prior Screening history receipt investigational antidiabetic drug within 3 month prior Screening . Prior treatment investigational study alogliptin . Hypersensitive pioglitazone HCl , metformin , alogliptin excipients . The patient donate 400 mL blood within 90 day prior Screening PreScreening , applicable .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Glucose Metabolism Disorder</keyword>
	<keyword>Dysmetabolic Syndrome</keyword>
	<keyword>Type II Diabetes</keyword>
	<keyword>Diabetes Mellitus , Lipoatrophic</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Hyperglycemia</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>